US · Healthcare · Biotechnology
EPS came in at -1.08 against a street estimate of -0.88 — a miss of 22.7%.
Analysts rate Stoke Therapeutics Inc a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $46.38.
CONFIDENT Stoke reported strong EMPEROR execution, reiterated a Q3 2027 readout and second-half 2027 NDA submission, and expects cash to fund operations into early 2028. Q3 FY26 Management estimates approximately 38,000 Dravet patients across the U.S., UK, EU4, and Japan, including about 16,000 in the U.S. Analysts focused on Vineland methodology, FDA review strategy, seizure-control thresholds, and STK-002 development. Management emphasized centralized data collection, no expected advisory committee, and the planned 2027 milestones. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.11% |
| RTW INVESTMENTS, LLC | 8.72% |
| FMR Inc | 8.23% |
| Lynx1 Capital Management, LP | 6.26% |
| Redmile Group, LLC | 6.12% |
| Wellington Management Company LLP | 5.45% |
| Morgan Stanley - Brokerage Accounts | 5.35% |
| Baker Bros Advisors LP | 5.17% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Stoke Therapeutics reported third-quarter 2026 revenue of $11.255 million, compared with $10.632 million in the third quarter of 2 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $11.3 million, up from $10.6 million in Q3 2025. • Q3 2026 net loss was $73.6 million, or $1.08 pe | 2026-10-29 |
| Board / officer change · Q3 2026 STOKE THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • New board member Alexander (Bo) Cumbo appointed September 23, 2026 • Initial stock option | 2026-09-25 |
| Quarterly report · Q2 2026 STOKE THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Equivalents: $110.0 million as of June 30, 2026 (up from $84.2 million Dec | 2026-08-03 |
| Company announcement · Q3 2026 STOKE THERAPEUTICS, INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Company filed prospectus supplement on August 3, 2026 for up to $200,000,000 in new | 2026-08-03 |
| Results announced · Q3 2026 STOKE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $420.0 million (comprised of $354.3 million as of June 30, 20 | 2026-08-03 |
| Reg FD disclosure · Q2 2026 STOKE THERAPEUTICS, INC. – 8-K SUMMARY (June 30, 2026) HEADLINE NUMBERS • Phase 3 EMPEROR study enrollment complete: 162 patients enrolled across U. | 2026-06-30 |
| Shareholder vote results · Q2 2026 STOKE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 3, 2026 • Three Class I directors elected to three-ye | 2026-06-04 |
Readable in the app.
| Announcement | Date |
|---|---|
| Lease agreement for new facility or production space Stoke Therapeutics filed an 8-K on January 27, 2026, disclosing a lease agreement. Item 2.03 of the filing references Item 1.01, which contains details about the lease arrangement. However, | 2026-01-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stoke Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.